LV13457B - Vaccine composition admixed with an alkylphosphatidylcholine - Google Patents

Vaccine composition admixed with an alkylphosphatidylcholine Download PDF

Info

Publication number
LV13457B
LV13457B LVP-06-70A LV060070A LV13457B LV 13457 B LV13457 B LV 13457B LV 060070 A LV060070 A LV 060070A LV 13457 B LV13457 B LV 13457B
Authority
LV
Latvia
Prior art keywords
les
des
dans
est
une
Prior art date
Application number
LVP-06-70A
Other languages
English (en)
Latvian (lv)
Inventor
Jean Haensler
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of LV13457B publication Critical patent/LV13457B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LVP-06-70A 2003-11-17 2006-05-15 Vaccine composition admixed with an alkylphosphatidylcholine LV13457B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0313406A FR2862306B1 (fr) 2003-11-17 2003-11-17 Composition vaccinale

Publications (1)

Publication Number Publication Date
LV13457B true LV13457B (en) 2007-01-20

Family

ID=34508504

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-06-70A LV13457B (en) 2003-11-17 2006-05-15 Vaccine composition admixed with an alkylphosphatidylcholine

Country Status (23)

Country Link
US (2) US7344720B2 (es)
EP (1) EP1696954B1 (es)
JP (1) JP4638880B2 (es)
KR (1) KR101136107B1 (es)
CN (1) CN1882358B (es)
AT (1) ATE412429T1 (es)
AU (1) AU2004290943B2 (es)
BR (1) BRPI0416670A (es)
CA (1) CA2545086C (es)
CY (1) CY1108498T1 (es)
DE (1) DE602004017504D1 (es)
DK (1) DK1696954T3 (es)
ES (1) ES2311875T3 (es)
FR (1) FR2862306B1 (es)
IL (1) IL175573A (es)
LT (1) LT5435B (es)
LV (1) LV13457B (es)
NO (1) NO20062779L (es)
PL (1) PL1696954T3 (es)
PT (1) PT1696954E (es)
SI (1) SI1696954T1 (es)
WO (1) WO2005049080A1 (es)
ZA (1) ZA200603522B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100752990B1 (ko) * 2006-08-02 2007-08-30 주식회사 대웅 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
AU2010247253A1 (en) * 2009-05-14 2012-01-12 Sanofi Pasteur Method for detoxification of lipopolysaccharide (LPS) or of lipid a of gram-negative bacteria
AU2010247252A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Method for admixing the lipopolysaccharide (LPS) of gram-negative bacteria
AU2010247254A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Menigococcus vaccine containing lipooligosaccharide (LOS) from modified strains of L6 immunotype Neisseria meningitidis
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
JP5761143B2 (ja) * 2011-11-02 2015-08-12 株式会社リコー 撮像ユニット、撮像ユニットを搭載した車両
US20140147475A1 (en) * 2012-11-29 2014-05-29 Antonius Arnoldus Christiaan Jacobs Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
MX357432B (es) 2013-03-18 2018-07-09 Intervet Int Bv Vacuna para proteger a un rumiante contra la neumonia causada por mannheimia haemolytica.
DK3171954T3 (en) 2014-07-21 2018-08-06 Sanofi Pasteur Sa LIQUID APPLICATION FOR THE GENERATION OF DROPS AND ITS USE FOR PREPARING A VACCINE COMPOSITION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
WO2002026209A2 (en) 2000-09-28 2002-04-04 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
JP4164361B2 (ja) * 2000-11-07 2008-10-15 イムノワクチン テクノロジーズ インコーポレーテッド 増強した免疫応答を有するワクチン、およびその調製方法
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use

Also Published As

Publication number Publication date
ATE412429T1 (de) 2008-11-15
DK1696954T3 (da) 2009-02-23
CA2545086A1 (en) 2005-06-02
CY1108498T1 (el) 2014-04-09
LT2006036A (en) 2007-05-25
IL175573A (en) 2010-06-30
DE602004017504D1 (de) 2008-12-11
US7344720B2 (en) 2008-03-18
LT5435B (lt) 2007-07-25
US7767658B2 (en) 2010-08-03
US20050208060A1 (en) 2005-09-22
JP2007511585A (ja) 2007-05-10
KR101136107B1 (ko) 2012-04-17
FR2862306A1 (fr) 2005-05-20
US20080131446A1 (en) 2008-06-05
BRPI0416670A (pt) 2007-02-13
AU2004290943B2 (en) 2009-08-27
EP1696954A1 (fr) 2006-09-06
NO20062779L (no) 2006-08-15
ZA200603522B (en) 2007-07-25
CA2545086C (en) 2011-11-08
WO2005049080A1 (fr) 2005-06-02
KR20060127385A (ko) 2006-12-12
PT1696954E (pt) 2008-11-25
EP1696954B1 (fr) 2008-10-29
ES2311875T3 (es) 2009-02-16
AU2004290943A1 (en) 2005-06-02
CN1882358B (zh) 2011-02-02
CN1882358A (zh) 2006-12-20
IL175573A0 (en) 2006-09-05
PL1696954T3 (pl) 2009-04-30
JP4638880B2 (ja) 2011-02-23
WO2005049080B1 (fr) 2005-09-01
SI1696954T1 (sl) 2009-04-30
FR2862306B1 (fr) 2008-05-30

Similar Documents

Publication Publication Date Title
LV13457B (en) Vaccine composition admixed with an alkylphosphatidylcholine
EP1326636B1 (fr) Composition vaccinale
EP1750707B1 (fr) Composition immunostimulante comprenant au moins un agoniste du récepteur Toll-like 7 ou du récepteur Toll-like 8 et un agoniste du récepteur Toll-like 4
JP2023526422A (ja) コロナウイルス抗原組成物及びそれらの使用
EP0015810B1 (fr) N-acétyl-L-(N-méthyl-alanyl)-D-isoglutamine et compositions la contenat, pour l'utilisation en tant que régulateurs des mécanismes immunitaires
CA3215771A1 (en) Virus vaccine
JP2010180253A (ja) 抗原または免疫原に対する免疫応答を仕立てる方法。
WO1989005631A1 (fr) Compositions presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
AU769390B2 (en) Vaccine composition
Rosales-Mendoza et al. RNA-based vaccines against SARS-CoV-2
CA2406949A1 (fr) Utilisation de vecteurs particulaires dans l'immunomodulation
US20240115693A1 (en) Sars-cov-2 antigen nanoparticles and uses there of
US20230321230A1 (en) Compositions and Methods for Adjuvanted Vaccines
CA2630530C (fr) Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral
CA3212936A1 (fr) Nouvelle application d'une composition immunogene ou vaccinale
FR2881050A1 (fr) Dcchol chez les nouveaux-nes
WO2004073596A2 (fr) Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires.